Kairos Pharma, Ltd. KAPA 深 滬
等待開盤 11-05 09:30:00 美东时间
0.8674
-0.143
-14.12%
華盛通- 最 高1.02
- 今 開1.00
- 成交量 86.89万股
- 最 低 0.8619
- 昨 收 1.01
- 總市值 1461.51万
- 52周最高 3.25
- 市盈率 靜 --
- 換手率 5.16%
- 52周最低 0.40
- 委 比 19.05%
- 總股本 1684.93万
- 歷史最高 4.00
- 量 比 4.53
- 振 幅 15.65%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
今天 10:35
D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.
11-04 22:30
Kairos Pharma Presents Phase 2 Trial Of ENV-105 In Advanced Prostate Cancer As ESMO Meeting
Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data
10-20 20:08
Kairos Pharma Approves RSUs and Cash Bonuses
Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On October 8, 2025,...
10-16 04:28
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
Kairos Pharma Announces Efficacy Data From Ongoing Phase 2 Clinical Trial Of ENV105 In Patients With Metastatic Castration-Resistant Prostate Cancer
Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety dataCompany to host virtual KOL discussion today to provide additional perspective on data
09-18 20:05
Kairos Pharma Presents Phase 1 Data at Conference
Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On September 3, 202...
09-03 20:48
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) rose sharply in pre-market t...
09-02 17:28
Kairos Pharma Q2 EPS $(0.08) Misses $(0.05) Estimate
Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent.
08-13 05:37
Kapa Gold Inc. Accelerates Warrant Expiry Date
An announcement from KAPA Gold Inc ( ($TSE:KAPA) ) is now available. Kapa Gold ...
08-12 03:02
